APA

Ware K. E., Hinz T. K., Kleczko E., Singleton K. R., Marek L. A., Helfrich B. A., Cummings C. T., Graham D. K., Astling D., Tan A. & Heasley L. E. (20130404). A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. : Oncogenesis.

Chicago

Ware K E, Hinz T K, Kleczko E, Singleton K R, Marek L A, Helfrich B A, Cummings C T, Graham D K, Astling D, Tan A-C and Heasley L E. 20130404. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. : Oncogenesis.

Harvard

Ware K. E., Hinz T. K., Kleczko E., Singleton K. R., Marek L. A., Helfrich B. A., Cummings C. T., Graham D. K., Astling D., Tan A. and Heasley L. E. (20130404). A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. : Oncogenesis.

MLA

Ware K E, Hinz T K, Kleczko E, Singleton K R, Marek L A, Helfrich B A, Cummings C T, Graham D K, Astling D, Tan A-C and Heasley L E. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. : Oncogenesis. 20130404.